SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing capacity

BACKGROUND: Scaling SARS-CoV-2 testing to meet demands of safe reopenings continues to be plagued by assay costs and supply chain shortages. In response, we developed SalivaDirect, which received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA). METHODS: We simplifi...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Med (N Y)
Main Authors: Vogels, Chantal B.F., Watkins, Anne E., Harden, Christina A., Brackney, Doug E., Shafer, Jared, Wang, Jianhui, Caraballo, César, Kalinich, Chaney C., Ott, Isabel M., Fauver, Joseph R., Kudo, Eriko, Lu, Peiwen, Venkataraman, Arvind, Tokuyama, Maria, Moore, Adam J., Muenker, M. Catherine, Casanovas-Massana, Arnau, Fournier, John, Bermejo, Santos, Campbell, Melissa, Datta, Rupak, Nelson, Allison, Dela Cruz, Charles S., Ko, Albert I., Iwasaki, Akiko, Krumholz, Harlan M., Matheus, J.D., Hui, Pei, Liu, Chen, Farhadian, Shelli F., Sikka, Robby, Wyllie, Anne L., Grubaugh, Nathan D.
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Inc. 2021
Assuntos:
Clinical and Translational Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7836249/
https://ncbi.nlm.nih.gov/pubmed/33521748
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.medj.2020.12.010
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados